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Abstract
Introduction: Human epidermal growth factor receptor 2 (HER2)-amplified breast cancers represent a tumor
subtype with chromosome 17q rearrangements that lead to frequent gene amplifications. The aim of this study
was to quantify the amplification of genes located on chromosome 17q and to analyze the relations between the
pattern of gene amplifications and the patients’ characteristics and survival.
Methods: Patients with HER2-positive breast tumors (HER2 score of 3+ by immunohistochemistry or positive for
HER2 amplification by fluorescence in situ hybridization (FISH)) (n = 86) and with HER2-negative breast tumors
(n = 40) (negative controls) were included in this study. Using a quantitative polymerase chain reaction method
and DNA extracted from frozen tumor specimens, 11 genes (MED1, STARD3, HER2, GRB7, THRA, RARA, TOP2A, IGFBP4,
CCR7, KRT20, KRT19 and GAS), which are localized within Chr17q12-q21 and have a putative role in breast cancer
development, were quantified. Relapse-free and overall survival rates were estimated from the date of surgery to
the date of the event of interest (recurrence or death) using the Kaplan-Meier method.
Results: Gene amplification was observed only in HER2-positive tumors, and the frequency of amplification
decreased with the distance of the gene from HER2. HER2 presented the highest level of amplification. TOP2A was
not included in the smallest region of amplification involving HER2. Amplification of RARA, KRT20 and KRT19 was
significantly associated with node-positive breast cancer (P = 0.030, P = 0.002 and P = 0.033, respectively). During a
median follow-up period of 55 months (range, 6 to 81 months), the subgroup of patients with hormone receptor-
negative cancer and without TOP2A amplification showed the worst survival (relapse-free survival: hazard ratio
(HR) = 0.29, 95% confidence interval (95% CI), 0.13 to 0.65, P = 0.001; and overall survival: HR = 0.28, 95% CI, 0.10 to
0.76, P = 0.008).
Conclusions: HER2 amplification seems to drive genomic instability along chromosome 17q, leading to different
patterns of gene amplification. This study confirms the clinical importance of identifying, among patients with
HER2-positive breast tumors, the subgroup of patients with hormone receptor-negative and nonamplified TOP2A
cancers as they have the worst prognosis.
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Introduction
Gene amplification at chromosome 17q (Chr17q) involves
the human epidermal growth factor receptor 2 (HER2)
gene and is observed in about 15% to 20% of breast can-
cers. HER2 amplification is associated with aggressive
tumor behavior (increased metastatic potential and
reduced survival), and it also predicts a patient’s response
to trastuzumab therapy [1,2]. Although HER2-positive
breast cancers are classified as a tumor subgroup, they
are quite heterogeneous. Indeed, they can be divided
more or less equally into hormone receptor-negative
(estrogen receptor/progesterone receptor-negative, or ER/
PR-negative) and hormone receptor-positive (ER/PR-posi-
tive) tumors. In the ER/PR-positive subgroup, develop-
ment of resistance to antihormonal therapy could be
explained by the cross-talk between the HER2 and ER
pathways [3]. Furthermore, first-line treatment of HER2-
positive breast cancers with trastuzumab presents
response rates that vary between 25% and 35%, and the
benefit of trastuzumab therapy has been shown only in
patients with high levels of HER2 amplification [4]. Com-
parative genomic hybridization arrays and fluorescence in
situ hybridization (FISH) studies have shown that HER2-
amplified breast cancers present a variety of alterations
on Chr17 and gene amplifications at Chr17q12-q21 are
particularly frequent and complex [5]. Among the genes
that are located in this region and have been reported to
be amplified in breast cancers, topoisomerase IIa
(TOP2A), a gene coding for the enzyme targeted by
anthracyclines, is located 2 Mb from HER2. TOP2A
amplification might be linked to the sensitivity to anthra-
cyclines observed in HER2-positive breast tumors [6-18].
Most of the published data indicate that TOP2A amplifi-
cation occurs only in HER2-amplified tumors. However,
some authors have reported cases in which TOP2A was
amplified also in the absence of HER2 amplification
[19,20]. Interestingly, the same studies do not support the
role of TOP2A amplification as a predictive marker for
response to anthracyclines. These works also report a dif-
ferent frequency of TOP2A amplifications and deletions.
The presence of TOP2A deletions, often analyzed
together with TOP2A amplification, has complicated the
question of the relations among TOP2A alteration, prog-
nosis and response to anthracyclines. Technical issues,
the cutoff levels used to classify a gene as amplified or
deleted and different quality assurance guidelines could
also explain these discrepancies [21,22].
Nevertheless, the molecular variations within the
Chr17q amplicon and their clinical implications remain
largely unknown. Indeed, besides TOP2A, other genes
which are located not only in the HER2 smallest region
of amplification (SRA) [23,24] but also all along the long
arm of the Chr17 [5,24-27] might also be amplified, and
they could play functional roles in breast cancer devel-
opment and progression. To explore this hypothesis, we
carried out a quantitative analysis of a set of 11 genes
that were chosen for their localization along Chr17q12-
q21 and for their putative role in breast cancer develop-
ment. Two genes were located on the centromeric side
(MED1 and STARD3), and nine were located on the dis-
tal side (GRB7, THRA, RARA, TOP2A, IGFBP4, CCR7,
KRT20, KRT19 and GAS) of Ch17q12-21 relative to
HER2 localization. The relation between gene amplifica-
tion and patients’ characteristics and survival was then
analyzed. We show that amplification of TOP2A and of
other genes distal to HER2 does not occur in tumors in
which HER2 is not amplified. We confirm that TOP2A
is not included in the SRA involving HER2 and describe
different copy number alterations along the distal side
of Chr17q. We also show that TOP2A nonamplification
is related to worse survival in the subpopulation patients
with of ER/PR-negative tumors.
Materials and methods
Patients’ characteristics, tumor samples and treatment
A total of 759 consecutive breast cancer patients referred
to the Val d’Aurelle Cancer Center between March 2002
and May 2005 were prospectively entered into the data-
base of a tumor DNA bank. Ethical approval was provided
by the local research ethics committee. All patients gave
their written, informed consent. The DNA bank was cre-
ated using frozen, histologically proven invasive breast
cancer specimens that were primarily handled for ER test-
ing by the dextran charcoal method. Patients with primary
HER2-positive breast cancer were initially selected on the
basis of the level of HER2 expression by immunohisto-
chemistry (IHC) using the HercepTest (DakoCytomation,
Trappes, France). HER2 scores of 0 and 1 were considered
negative. HER2 scores of 2+ were then checked by FISH
for HER2 copy number (PathVysion HER-2 DNA Probe
Kit; Abbott Molecular, Rungis, France). Only patients with
HER2 scores of 3+ derived by IHC or positive for HER2
amplification by FISH were considered HER2-positive.
HER2 copy number and Chr17 polysomy were then
assessed by quantitative polymerase chain reaction (qPCR)
as previously described [28]. Patients presenting with
Chr17 polysomy without true HER2 amplification were
excluded from the study. Adjuvant treatment was dis-
cussed in multidisciplinary medical meetings according to
local and international guidelines and submitted for each
patient’s approval. All patients were treated at least by
adjuvant radiation therapy and received anthracycline-
based adjuvant therapy according to the medical standards
at the time of diagnosis. Considering the patient accrual
period, and despite their HER2-positive status, women
were not treated with adjuvant anti-HER2 therapy, with
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the exception of patients included in a clinical trial to
assess the benefits of trastuzumab as adjuvant therapy.
The clinicopathologic characteristics and treatments are
summarized in Table 1. Patients received regular follow-
up examinations, that is, every 6 months for the first 5
years, then yearly after that.
DNA extraction and gene quantification
Each frozen tumor specimen was pulverized in liquid
nitrogen with an automatic grinder (Cryobroyeur 2000P
Automatique; Rivoire, Montpellier, France), homoge-
nized in a Polytron homogenizer in buffer (20 mM Tris
HCI, 1.5 mM ethylenediaminetetraacetic acid (EDTA),
10 mM Na2MoO4, 1.5 mM dithiothreitol and 10% gly-
cerol, pH 7.4) (buffer:tissue ratio was 10:1 (vol/wt)) used
for ER and PR measurement and centrifuged at 10,000
× g for 15 minutes. Total genomic DNA was extracted
from the pellet. The DNA concentration was deter-
mined by measuring the absorbance at 260 nm, and all
samples had a 260/280-nm ratio higher than 1.7. DNA
was stored at -20°C in TE buffer (10 mM Tris and
0.5 mM EDTA, pH 7.6). All procedures were carried
out at 4°C unless noted otherwise. qPCR amplifications
were performed with 10 ng of DNA on a Rotorgene
6000 apparatus (Qiagen, Courtaboeuf, France) using
ABsolute Blue qPCR SYBR Green Mix (ref AB-4167;
ThermoFisher Scientific, Illkirch, France) with an initial
15-minute denaturation step at 95°C followed by
40 cycles. The cycling temperatures and the primers
used for each gene are summarized in Table 2. After
completion of the amplification, samples were subjected
to a temperature ramp (from the annealing temperature
to 95°C with a transition rate of 0.1°C/s) with continu-
ous fluorescence monitoring for melting curve analysis.
MED1, STARD3, HER2, GRB7, THRA, RARA, TOP2A,
IGFBP4, CCR7, KRT20, KRT19 and GAS amplification
levels were normalized to those of the somatostatin
receptor type II (SSTR2) gene that is localized on
Chr17q24. HER2 quantification was also normalized to
the expression values of glyceraldehyde 3-phosphate
dehydrogenase (GAPDH), which is localized on chromo-
some 12p13, and of b-actin (ACBT), which is localized
on chromosome 7p22, as controls for polysomy. SSTR2
quantification was also normalized to GAPDH and
ACBT to detect SSTR2 amplification. Quantification was
obtained by constructing a standard curve from serial
dilutions of normal genomic DNA (ref 11 691 112 001;
Roche, Meylan, France). For HER2 amplification, geno-
mic DNA from SKBR3 cells was used as a positive con-
trol and DNA from MCF-7 cells was used as a negative
control. Water was used as a negative control for PCR
contamination. A gene was considered to be amplified
when the target gene-to-reference gene ratio was ≥2,
and it was considered to be deleted when the target
gene-to-reference gene ratio was ≤0.5.
Statistical analysis
Categorical variables were described using frequency
distributions, and continuous variables were stated using
medians and ranges. Correlations between genes was
evaluated using the Spearman’s r correlation. Associa-
tion between categorical variables was assessed with
the c2 test (or Fisher’s exact test when appropriate).
Differences were considered statistically significant when
Table 1 Patients’ characteristicsa
Characteristic Number of patients (%)
(n = 86)
Age, yr
<50 33 (38.4%)
≥50 53 (61.6%)
T
1 35 (40.7%)
2 46 (53.5%)
3 4 (4.6%)
4 1 (1.2%)
N
N+ 51 (59.3%)
N- 35 (40.7%)
SBR
2 36 (42.3%)
3 49 (57.7%)
Missing 1
Hormone receptor status
ER
ER- 60 (69.8%)
ER+ 26 (30.2%)
PR
PR- 44 (51.2%)
PR+ 42 (48.8%)
ER/PR
ER-/PR- 42 (48.9%)
ER-/PR+ 18 (20.9%)
ER+/PR- 2 (2.3%)
ER+/PR+ 24 (27.9%)
Treatment
Chemotherapy
Anthracyclines 42 (48.8%)
Anthracyclines and taxanes 26 (30.2%)
No chemotherapy 18 (21.0%)
Radiation therapy 86 (100.0%)
Antihormone therapy 34 (39.5%)
Trastuzumab 20 (23.3%)
Outcomes
Recurrence 25 (29.1%)
Death 17 (20.0%)
aT, tumor size; N, lymph node status; SBR, Scarff-Bloom-Richardson histological
grade; ER, estrogen receptor; PR, progesterone receptor.
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P < 0.05. Survival rates were estimated from the date of
surgery to the date of the event of interest using the
Kaplan-Meier method. The median survival was calcu-
lated with 95% confidence interval (95% CI). For overall
survival (OS), the event of interest was death, regardless
of the cause. Patients lost to follow-up were censored at
the last documented visit. For relapse-free survival
(RFS), the event of interest was recurrence. Patients who
were alive at the last follow-up examination and without
recurrence were censored at the time of the last follow-
up examination. Patients who died without recurrence
were censored at the date of death. Differences in survi-
val rates were compared using a log-rank test. Statistical
analyses were performed with Stata 10.0 software (Stata
Corp., College Station, TX, USA).
Results
Description of the study population
Eighty-six patients with HER2-amplified breast cancer
were included in the study. The median follow-up per-
iod was 55 months (range, 6 to 81 months). A total of
25 patients (29%) relapsed after a median of 18 months
from the date of surgery (range, 2 to 71 months), and
17 patients (20%) died after a median of 31 months
(range, 6 to 78 months). The 5-year RFS rate was 69%
(95% CI, 57% to 78%) and the 5-year OS rate was 79%
(95% CI, 67% to 87%). There were no statistical associa-
tions between RFS or OS and the adjuvant treatment
administered. The distribution of tumors relative to
their pattern of amplified and nonamplified genes was
homogeneous in the different treatment groups.
Table 2 Primer sequences and qPCR conditions used to quantify MED1, STARD3, HER2, GRB7, THRA, RARA, TOP2A,
IGFBP4, CCR7, KRT20, KRT19, GAS, ACBT, GAPDH and SSTR2a
GenBank accession
number
Gene name/primer Sequence 5’-3’ Size
nt
GC, % Amplicon,
bp
Annealing
temperature
NP_004765 MED1 sense ATT CTC CTG GGC TTC TCC AA 20 50% 97 54°C
MED1 antisense CCA CAC ACC AGG GAG TCA TT 20 55%
NP_006795 STARD3 sense CAG GCT GCT AGG GTG TAA CTG 21 57% 114 64°C
STARD3 antisense GAC AGA GCA CCG GAG AAC AG 20 60%
NM_004448 HER2 sense GCT CCC CAT ATG TCT CCC G 19 63% 101 58°C
HER2 antisense CCG GAC ATG GTC TAA GAG GC 20 60%
NP_005301 GRB7 sense CTC TGG CTC AGA ACT TCC TGA AT 23 48% 142 60°C
GRB7 antisense GTG CCC TTG GTG GAG TAA TAG AG 23 52%
NP_003241 THRA sense GTG GAC AAG ATC GAG AAG AGT CAG 24 50% 119 60°C
THRA antisense AGG TCA GTC ACC TTC ATC AGC AG 23 52%
NP_000955 RARA sense GGA GTG CTC AGA GTG GGT TC 20 60% 110 64°C
RARA antisense AGA AGG TCA TGG TGT CCT GCT C 22 55%
NP_001058 TOP2A sense GAT TCT GGA CCA ACC TTC AAC TA 23 43% 121 58°C
TOP2A antisense ATG TAC CAT CCT ACT ATC AAC TCA CTT T 28 36%
NP_001543 IGFBP4 sense CTC TTC CGG TGC TGA CCT CT 20 60% 146 60°C
IGFBP4 antisense GGT GCT CCG GTC TCG AAT 18 61%
NP_001829 CCR7 sense AGG CTA AAT CCC AGC CAG AG 20 55% 127 58°C
CCR7 antisense CTG TGG TGT TGT CTC CGA TG 20 55%
XP_352920 KRT20 sense ATG GCT TCA GAA GGA CCA GTT 21 48% 95 56°C
KRT20 antisense TGG AGA TCA GCT TCC ACT GTT A 22 45%
NP_002267 KRT19 sense TGA CAT GCG AAG CCA ATA TG 20 45% 124 56°C
KRT19 antisense AAA GCC CTC CCC TTC CTA AC 20 55%
X00183 GAS sense TCT CCC CAG ACT GGC TCT GA 20 60% 146 64°C
GAS antisense GCC GAA GTC CAT CCA TCC AT 20 55%
NP_001041 SSTR2 sense GCC TCC AGG GTC CAT TAA GG 20 60% 101 60°C
SSTR2 antisense ATT GAG TGG CTC ATC CGC C 19 58%
NP_001092 ACBT sense CCA CAC TGT GCC CAT CTA CG 20 60% 99 65°C
ACBT antisense AGG ATC TTC ATG AGG TAG TCA GTC AG 26 46%
NT_009759 GAPDH sense CTC ACG TAT TCC CCC AGG TT 20 55% 161 58°C
GAPDH antisense CCC AAA GCA CAT TTC TTC CA 20 45%
aqPCR, quantitative polymerase chain reaction; MED1, mediator complex subunit 1 gene; STARD3, steroidogenic acute regulatory-related lipid transfer (START)
domain containing 3 gene; HER2, human epidermal growth factor receptor 2 gene; GRB7, growth factor receptor-bound protein 7 gene; THRA, thyroid hormone
receptor a gene; RARA, retinoic acid receptor a gene; TOP2A, topoisomerase IIa gene; IGFBP4, insulin-like growth factor-binding protein 4 gene; CCR7, C-C
chemokine receptor type 7 gene; KRT20, cytokeratin 20 gene; KRT19, cytokeratin 19 gene; GAS, gastrin gene; ACBT, b-actin gene; GAPDH, glyceraldehyde 3-
phosphate dehydrogenase gene; SSTR2, somatostatin receptor type II gene.
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Analysis of the Chr17q12-q21 amplicon by qPCR
The variability in the efficiency of each parameter was
between 92% and 105% with a standard deviation of
0.04. The reference genes (SSTR2, GAPDH and ACBT)
were chosen in regions previously described as present-
ing a low level of instability or amplification [25,26] and
were controlled together to detect amplification. Their
crossing point values were 19.2 ± 0.56, 18.7 ± 0.47 and
17.6 ± 0.43, respectively. The absence of SSTR2 amplifi-
cation was confirmed in all samples by measuring the
SSTR2:GAPDH and SSTR2:ACBT ratios, which in all
cases were <1.5. Finally, none of the 40 HER2-negative
cancer specimens (negative controls) showed amplifica-
tion of the studied genes. The status (amplified, deleted
or normal) of the 11 genes (MED1, STARD3, GRB7,
THRA, RARA, TOP2A, IGFBP4, CCR7, KRT20, KRT19
and GAS) evaluated in the 86 HER2-positive cancer
samples is summarized in Table 3. Coamplification with
HER2 occurred in 65.1% of samples for MED1 (56 of
86), 93% for STARD3 (80 of 86), 97.7% for GRB7 (84 of
86), 54.7% for THRA (47 of 86), 26.7% for RARA (23 of
86), 26.7% for TOP2A (23 of 86), 20.9% for IGFBP4 (18
of 86), 20.9% for CCR7 (18 of 86), 14% for KRT20 (12
of 86), 11.6% for KRT19 (10 of 86) and 7% for GAS (6
of 86). HER2 presented the highest level of amplification
(mean, 6.4; range, 2 to 32), whereas the frequency of
amplification of the other genes decreased according to
the distance of the gene from HER2 (Figure 1). The
amplification levels of HER2 and of the other genes
were compared by linear regression analysis. HER2
amplification levels were correlated only with the ampli-
fication levels of MED1 (r = 0.84), STARD3 (r = 0.87)
and GRB7 (r = 0.93), but not of other genes, particularly
TOP2A (r = 0.65). Gene deletions occurred in fewer
than 5.8% of the samples, regardless of the gene studied
(Table 3).
Relation between the pattern of gene amplification and
clinical characteristics
Node status (N), Scarff-Bloom-Richardson histological
(SBR) grade and ER/PR-negative status were signifi-
cantly associated with worse outcomes in terms of both
RFS rate (P = 0.007, P = 0.004 and P = 0.024, respec-
tively) and OS rate (P = 0.020, P = 0.048 and P = 0.076,
respectively) (univariate analysis) (see Table 4 and
Figure 2 for ER/PR status). The patterns of gene amplifi-
cation were not significantly correlated with the T or
SBR grade. Conversely, MED1 amplification tended to
be associated with ER-positive tumors (P = 0.072),
whereas amplification of RARA, KRT20 or KRT19 was
significantly associated with node-positive breast cancers
(P = 0.030, P = 0.002 and P = 0.033, respectively). More-
over, patients with TOP2A-amplified tumors tended to
have better RFS rates (hazard ratio (HR) = 0.47, 95% CI
Table 3 Gene amplification quantification relative to the
SSTR2 reference genea
Gene Number of patients (%)
(n = 86)
Median (range)
MED1
Deletion 3 (3.5%) 0.5 (0.5 to 0.5)
Normal 27 (31.4%) 0.9 (0.6 to 1.9)
Amplification 56 (65.1%) 4.6 (2 to 27.8)
Total 86 (100.0%) 2.6 (0.5 to 27.8)
STARD3
Deletion 0 -
Normal 6 (7.0%) 1.5 (0.7 to 1.9)
Amplification 80 (93.0%) 6.4 (2.0 to 74.9)
Total 86 (100.0%) 5.9 (0.7 to 74.9)
HER2
Amplification 86 (100.0%) 6.4 (2 to 32)
GRB7
Deletion 0 -
Normal 2 (2.3%) 1.1 (0.6 to 1.7)
Amplification 84 (97.7%) 6.8 (2.3 to 36.5)
Total 86 (100.0%) 6.6 (0.6 to 36.5)
THRA
Deletion 1 (1.2%) 0.5
Normal 38 (44.2%) 1.1 (0.6 to 1.9)
Amplification 47 (54.7%) 4.4 (2.0 to 11.7)
Total 86 (100.0%) 2.2 (0.5 to 11.7)
RARA
Deletion 3 (3.5%) 0.5 (0.4 to 0.5)
Normal 60 (69.8%) 1.0 (0.6 to 1.9)
Amplification 23 (26.7%) 3.4 (2.0 to 11.1)
Total 86 (100.0%) 1.1 (0.4 to 11.1)
TOP2A
Deletion 4 (4.7%) 0.5 (0.5 to 0.5)
Normal 59 (68.6%) 1.0 (0.6 to 1.8)
Amplification 23 (26.7%) 3.2 (2 to 7)
Total 86 (100.0%) 1.1 (0.5 to 7)
IGFBP4
Deletion 5 (5.8%) 0.5 (0.5 to 0.5)
Normal 63 (73.3%) 1.0 (0.6 to 1.9)
Amplification 18 (20.9%) 3.1 (2 to 8)
Total 86 (100.0%) 1.1 (0.5 to 8)
CCR7
Deletion 3 (3.5%) 0.4 (0.4 to 0.5)
Normal 65 (75.6%) 0.9 (0.6 to 1.8)
Amplification 18 (20.9%) 3.3 (2 to 14.9)
Total 86 (100.0%) 1.0 (0.4 to 14.9)
KRT20
Deletion 2 (2.3%) 0.5 (0.5 to 0.5)
Normal 72 (83.7%) 1.1 (0.6 to 1.8)
Amplification 12 (14.0%) 3.1 (2.3 to 11.6)
Total 86 (100.0%) 1.1 (0.5 to 11.6)
KRT19
Deletion 5 (5.8%) 0.5 (0.5 to 0.5)
Normal 71 (82.6%) 1.0 (0.6 to 1.8)
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0.16 to 1.38, P = 0.159) and OS rates (HR = 0.34, 95%
CI 0.08 to 1.48, P = 0.132) than patients with TOP2A
nonamplified tumors (Figure 2). The subgroup of
patients with ER/PR-negative cancers without amplifica-
tion of TOP2A in particular had the worst RFS rates
(HR = 0.29, 95% CI 0.13 to 0.65, P = 0.001) and
the worst OS rates (HR = 0.28, 95% CI 0.10 to 0.76,
P = 0.008).
Discussion
In this work, we quantified gene amplification in the
17q12 to 17q21 region around HER2 in HER2-amplified
breast tumors. Among the patients with primary breast
cancer, fewer than 12% had HER2-positive tumors. This
result is in accordance with recent studies reporting 12%
to 15% of HER2 amplification compared to the 20% to
25% found in historical studies [29,30], in which Chr17
Table 3 Gene amplification quantification relative to the
SSTR2 reference genea (Continued)
Amplification 10 (11.6%) 3.0 (2 to 6.4)
Total 86 (100.0%) 1.0 (0.5 to 6.4)
GAS
Deletion 2 (2.3%) 0.5 (0.4 to 0.5)
Normal 78 (90.7%) 1.0 (0.6 to 1.7)
Amplification 6 (7.0%) 2.8 (2 to 14.4)
Total 86 (100.0%) 1.0 (0.4 to 14.4)
aAmplification: target gene/SSTR2 ratio ≥2; deletion: target gene/SSTR2 ratio
≤0.5; normal: 0.5 < target gene/SSTR2 ratio <2. MED1, mediator complex
subunit 1 gene; STARD3, steroidogenic acute regulatory-related lipid transfer
(START) domain containing 3 gene; HER2, human epidermal growth factor
receptor 2 gene; GRB7, growth factor receptor-bound protein 7 gene; THRA,
thyroid hormone receptor a gene; RARA, retinoic acid receptor a gene; TOP2A,
topoisomerase IIa gene; IGFBP4, insulin-like growth factor-binding protein 4
gene; CCR7, C-C chemokine receptor type 7 gene; KRT20, cytokeratin 20 gene;
KRT19, cytokeratin 19 gene; GAS, gastrin gene; SSTR2, somatostatin receptor
type II gene.
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Figure 1 Gene amplification distribution on chromosome 17q12-q21 in Human epidermal growth factor receptor 2 (HER2)-positive
breast cancer specimens on the basis of the overview of chromosome 17 with the National Center for Biotechnology Information’s
Sequence Viewer version 2.9 database [55]. The frequency of amplification (percentage of positive breast cancer specimens on the y-axis) for
a gene decreases with the increase of its distance from HER2. MED1, mediator complex subunit 1 gene; STARD3, steroidogenic acute regulatory-
related lipid transfer (START) domain containing 3 gene; HER2, human epidermal growth factor receptor 2 gene; GRB7, growth factor receptor-
bound protein 7 gene; THRA, thyroid hormone receptor a gene; RARA, retinoic acid receptor a gene; TOP2A, topoisomerase IIa gene; IGFBP4,
insulin-like growth factor-binding protein 4 gene; CCR7, C-C chemokine receptor type 7 gene; KRT20, cytokeratin 20 gene; KRT19, cytokeratin
19 gene; GAS, gastrin gene.
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Table 4 Univariate analysis of the different variablesa
RFS OS
Variable Number of patients Events 5-year RFS HR (95% CI) Events 5-year OS HR (95% CI)
T
1 35 8 74.2 1 6 84.2 1
2 46 15 65.9 1.51 (0.64 to 3.58) 10 74.3 1.30 (0.47 to 3.60)
3 or 4 5 2 53.3 2.15 (0.45 to 10.4) 1 80.0 1.34 (0.16 to 11.3)
P = 0.510* P = 0.868*
N
N- 35 4 88.1 1 2 94.2 1
N+ 51 21 55.8 3.94 (1.35 to 11.5) 15 70.0 4.89 (1.12 to 21.4)
P = 0.007* P = 0.020*
SBR
2 36 5 84.9 1 4 89.4 1
3 49 20 55.8 3.80 (1.42 to 10.2) 13 70.8 2.96 (0.96 to 9.15)
P = 0.004* P = 0.048*
ER
ER- 60 19 66.9 1 13 76.2 1
ER+ 26 6 70.1 0.64 (0.25 to 1.60) 4 84.9 0.68 (0.22 to 2.10)
P = 0.333* P = 0.505*
PR
PR- 44 18 57.6 1 13 67.3 1
PR+ 42 7 80.9 0.36 (0.15 to 0.87) 4 92.4 0.32 (0.10 to 0.99)
P = 0.018* P = 0.037*
ER/PR
ER-/PR- 42 17 58.7 1 12 68.9 1
Other 44 8 78.2 0.39 (0.17 to 0.91) 5 89.2 0.40 (0.14 to 1.14)
P = 0.024* P = 0.076*
MED1
Del/Nm 30 10 66.2 1 7 72.9 1
Amp 56 15 70.0 0.76 (0.34 to 1.70) 10 82.5 0.63 (0.23 to 1.69)
P = 0.507* P = 0.354*
STARD3
Del/Nm 6 2 55.6 1 2 53.3 1
Amp 80 23 69.4 0.85 (0.20 to 3.62) 15 80.9 0.48 (0.11 to 2.14)
P = 0.826* P = 0.327*
GRB7
Del/Nm 2 1 50.0 1 1 0.00 1
Amp 84 24 69.3 0.30 (0.04 to 2.33) 16 80.1 0.15 (0.02 to 1.20)
P = 0.225* P = 0.038*
THRA
Del/Nm 39 16 59.0 1 11 73.8 1
Amp 47 9 79.3 0.50 (0.22 to 1.13) 6 84.7 0.53 (0.19 to 1.43)
P = 0.090* P = 0.199*
RARA
Del/Nm 63 21 64.1 1 15 75.2 1
Amp 23 4 82.4 0.50 (0.17 to 1.45) 2 91.3 0.36 (0.08 to 1.59)
P = 0.190* P = 0.162*
TOP2A
Del/Nm 63 21 63.7 1 15 74.8 1
Amp 23 4 82.4 0.47 (0.16 to 1.38) 2 91.3 0.34 (0.08 to 1.48)
P = 0.159* P = 0.132*
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polysomy may have led to discordant interpretations
between higher signals due to polysomy and those due to
an absolute increase of HER2 gene copy number in a sig-
nificant proportion of cases [31]. Gene amplification on
the centromeric side (MED1 and STARD3) and the distal
side (GRB7, THRA, RARA, TOP2A, IGFBP4, CCR7,
KRT20, KRT19 and GAS) relative to HER2 localization
on Chr17q was determined by qPCR, an efficient method
for performing copy number analysis [32], and with refer-
ence genes located on Chr17 (SSTR2) and Chr4 and Chr2
(GAPDH and ACBT, respectively) to differentiate polys-
omy from true amplification. In fact, tumors presenting
only Chr17 polysomy should not be considered as HER2-
amplified, and patients with this presentation might not
benefit from anti-HER2 therapy, although these tumors
present moderate HER2 overexpression [28,33], but only
as a result of treatment with anthracyclines [34].
We have confirmed that gene amplification, including
that of TOP2A, occurs only in patients with HER2-
amplified breast tumors. We then showed that HER2
presents the highest amplification value and that the fre-
quency of amplification of a gene decreases with its
distance from HER2. These results suggest that instabil-
ity within Chr17q is driven by HER2 amplification.
Indeed, HER2-positive tumors have higher levels of
overall genomic instability than HER2-negative tumors,
supporting the idea that HER2 amplification is the key
amplicon driver on Chr17q [35,36]. Moreover, we found
a correlation between the amplification levels of HER2
and that of MED1, STARD3 and GRB7, but not of
TOP2A and the other genes localized on the distal side
of Chr17q. Therefore, the SRA of HER2 seems to be
limited to a small number of genes, among which are
STARD3 and GRB7 as described by Katoh et al. [37]
and as recently reported by Beroukhim et al. [38] in dif-
ferent cancer types. Kuwahara et al. [39] identified a
region between HER2 and GRB7 (a gene located 47 kb
from HER2) that contains a recombinant hot spot for
amplification, deletion and translocation. This site might
be located between GRB7 and THRA, a gene located
315 kb from GRB7, given that 84 (97.7%) of the cancer
specimens we assessed presented GRB7 amplification,
whereas only 47 (54.7%) showed THRA amplification.
The presence of this hot spot might explain why the
Table 4 Univariate analysis of the different variablesa (Continued)
IGFBP4
Del/Nm 68 21 66.6 1 15 76.9 1
Amp 18 4 77.4 0.70 (0.24 to 2.06) 2 88.9 0.49 (0.11 to 2.16)
P = 0.520* P = 0.335*
CCR7
Del/Nm 68 21 67.0 1 16 75.3 1
Amp 18 4 75.4 0.66 (0.22 to 1.93) 1 94.4 0.21 (0.03 to 1.61)
P = 0.442* P = 0.099*
KRT20
Del/Nm 74 21 69.2 1 15 78.8 1
Amp 12 4 66.7 1.31 (0.45 to 3.81) 2 81.5 1.02 (0.23 to 4.49)
P = 0.622* P = 0.981*
KRT19
Del/Nm 76 23 67.6 1 16 78.3 1
Amp 10 2 78.7 0.70 (0.16 to 2.96) 1 90.0 0.64 (0.08 to 4.82)
P = 0.624* P = 0.658*
GAS
Del/Nm 80 24 68.0 1 16 79.1 1
Amp 6 1 83.3 0.64 (0.09 to 4.74) 1 83.3 1.21 (0.16 to 9.20)
P = 0.660* P = 0.852*
ER-/PR- and TOP2A
Del/Nm
30 15 49.2 1 11 61.0 1
Others 56 10 79.2 0.29 (0.13 to 0.65) 6 89.7 0.28 (0.10 to 0.76)
P = 0.001* P = 0.008*
aT, tumor size; N, lymph node status; SBR grade, Scarff-Bloom-Richardson histological grade; ER, estrogen receptor; PR, progesterone receptor; Del, deletion; Nm,
normal; Amp, amplification; RFS, relapse-free survival; OS, overall survival; HR, hazard ratio; 95% CI, 95% confidence interval; MED1, mediator complex subunit 1
gene; STARD3, steroidogenic acute regulatory-related lipid transfer (START) domain containing 3 gene; HER2, human epidermal growth factor receptor 2 gene;
GRB7, growth factor receptor-bound protein 7 gene; THRA, thyroid hormone receptor a gene; RARA, retinoic acid receptor a gene; TOP2A, topoisomerase IIa
gene; IGFBP4, insulin-like growth factor-binding protein 4 gene; CCR7, C-C chemokine receptor type 7 gene; KRT20, cytokeratin 20 gene; KRT19, cytokeratin 19
gene; GAS, gastrin gene; SSTR2, somatostatin receptor type II gene; *log-rank test.
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Figure 2 Kaplan-Meier curves for relapse-free survival (RFS) and overall survival (OS). (a) Estrogen receptor/progesterone receptor (ER/PR)
status. Blue line indicates ER- and PR-negative (ER-/PR-) status; black line indicates ER-, PR- or ER/PR-positive (ER-/PR+, ER+/PR- or ER+/PR+) status.
(b) Topoisomerase IIa (TOP2A) amplification. Blue line indicates deleted or nonamplified (normal) TOP2A (TOP2A Del/N); black line indicates
amplified TOP2A (TOP2A Amp). For RFS, P = 0.159; for OS, P = 0.132. (c) TOP2A and ER/PR status. Blue line indicates ER- and PR-negative (ER-/PR-)
and deleted or nonamplified TOP2A (TOP2A Del/N); black line indicates ER-, PR-, or ER/PR-positive (ER-/PR+, ER+/PR- and ER+/PR+) status and
amplified TOP2A (TOP2A Amp). For RFS, P = 0.001; for OS, P = 0.008.
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frequency of recombination for a gene is higher when it
is located closer to HER2 and gradually decreases for
genes located far away from HER2. In general, the gene
amplification architectures derived from our results
illustrate the complexity of the rearrangement mechan-
isms (sister chromatid breakage-fusion-bridge cycles,
formation and reinsertion of double minutes and
repeated units at a single locus) and highlight the diver-
sity of HER2-amplified cancers [40,41].
Finally, we found a low overall number of deletions
(<5.8%), regardless of the gene analyzed. For TOP2A,
the deletion rate was 4.7%, which is low compared with
values found in other studies (between 8.1% and 35%)
[22]. This might be explained by the fact that in hetero-
genic tumors, which simultaneously present amplifica-
tions and deletions, qPCR cannot detect deletions that
are present in a very small number of cells. It is also
possible that in certain studies the percentage of tumors
with deletions was overestimated as a result of poor
standardization of the FISH technique. Indeed, Di Leo
et al. [42,43] recently showed high interlaboratory varia-
tions for TOP2A quantification, whereas Press et al. [44]
found a deletion rate comparable to ours in a prospec-
tive study using standardized FISH.
We then investigated the clinical impact of Chr17
anomalies. Amplification of RARA, KRT20 and KRT19
correlated with node invasion, suggesting that tumors
with amplification of genes on the distal side of Chr17q
are more aggressive than tumors with amplifications
restricted to the SRA of HER2. MED1 amplification
showed a tendency to be associated with ER-positive
tumors. MED1 encodes the mediator complex subunit 1
(MED1) [45] that anchors mediator to ERb [46] while
also interacting with ERa [47]. Although our study did
not show any significant impact of MED1 amplification
on survival, the prognostic value of MED1 should never-
theless be evaluated in a larger ER/PR-positive popu-
lation. Similarly, TOP2A amplification was not a
statistically significant prognostic factor, but patients
with tumors in which TOP2A was amplified tended to
have better RFS and OS rates (see Figure 2b). This
result is in accord with a recent study in which patients
with HER2-positive, TOP2A-amplified cancers presented
a trend of better survival than patients with HER2-posi-
tive breast cancers with deleted or normal TOP2A [48].
Conversely, the subgroup of patients with ER/PR-nega-
tive breast cancers and nonamplified (normal or deleted)
TOP2A showed the least favorable RFS and OS rates in
our population. We could not determine whether the
prognosis was even less favorable in the case of ER/PR-
negative tumors with TOP2A-deleted status than of
tumors with normal TOP2A. Nevertheless, TOP2A dele-
tions, which are often heterozygous [49], do not result
in total loss of expression of the protein [50]. Their
unfavorable prognosis might be explained by the fact
that ER/PR-negative, TOP2A nonamplified tumors may
not be responsive to hormone therapy and/or to anthra-
cycline-based therapy because of the absence or insuffi-
cient number of targets. Adjuvant therapy would thus
not be beneficial for these patients. Indeed, recent find-
ings suggest that the presence of TOP2A deletions is
not associated with better chemosensitivity or response
to anthracyclines, while the occurrence of TOP2A
amplifications may identify a subgroup of patients with
increased response to anthracyclines [18,44]. Many stu-
dies have been conducted on the impact of the presence
of HER2 and TOP2A amplifications on survival and
response to chemotherapy. Only a few studies found
that there was no benefit to treating patients with
HER2-positive cancer with anthracyclines or that
TOP2A amplification had no predictive value. The sub-
ject remains controversial [51], but nevertheless two
large trials (the National Surgical Adjuvant Breast and
Bowel Project B-11 and the National Cancer Institute of
Canada MA.5 studies) have retrospectively shown a cor-
relation between HER2 amplification and benefit from
adjuvant anthracycline-based chemotherapy [52,53].
Moreover, a pooled analysis that included 8 studies and
1,536 HER2-positive patients indicated that anthracy-
clines were superior to non-anthracycline-based regi-
mens in terms of disease-free and overall survival [54].
Conclusions
Few studies have used qPCR to assess gene copy num-
ber alterations in HER2-amplified breast cancer. The
assay we have developed can be used to assess the
amplification status of multiple genes. We have shown
that MED1, STARD3, TOP2A, GRB7, THRA, RARA,
IGFBP4, CCR7, KRT19, KRT20 and GAS amplification
occurred only in HER2-amplified breast cancers with
variable frequencies. We have confirmed that HER2
seems to drive genomic instability along Chr17q and
that TOP2A was not included in the SRA of HER2. The
different patterns of amplification we observed suggest
complex amplification mechanisms leading to a variety
of subtypes. RARA, KRT19 and KRT20 amplification
could be related to a more invasive breast cancer profile.
Moreover, we confirm the clinical importance of identi-
fying the subgroup of patients with ER/PR-negative,
TOP2A nonamplified cancer, as they have the worst
prognosis. A prospective study including a larger num-
ber of patients treated with trastuzumab and anthracy-
cline-based adjuvant therapy would be useful to
determine the predictive value of TOP2A amplification
and the prognostic value of gene copy number varia-
tions along Chr17q.
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